Intraventricular immunovirotherapy; a translational step forward.

Abstract

Oncolytic virotherapy with intratumoral engineered type-1 herpes simplex virus (HSV) has been proven safe with promising efficacy in recent clinical trials for treatment of both pediatric and adult high-grade glioma. However, this approach excludes patients with tumors in surgically inaccessible and/or eloquent brain regions. Current delivery methods are also unable to access/treat those patients with metastatic disease in the spinal cord and/or leptomeningeal disease. A recent preclinical study has paved the way for clinical translation of intraventricular administration of oHSV by identifying and mitigating the toxicity associated with this route for therapeutic benefit in murine models of disseminated medulloblastoma. This work may ultimately allow for targeting of intractable disease and provides a feasible option for the repetitive dosing of clinically relevant immunovirotherapy, G207.

• Authors: Joshua D Bernstock, Sarah Blitz, Kyung-Don Kang, Gregory K Friedman
• Journal: Oncotarget (Oncotarget) Vol. 14 Pg. 40-43 (01 12 2023) ISSN: 1949-2553 [Electronic] United States
• PMID: 36634220 (Publication Type: Journal Article)

Topics

• Adult
• Humans
• Child
• Mice
• Animals
• Oncolytic Viruses (genetics)
• Simplexvirus
• Oncolytic Virotherapy (methods)
• Glioma
• Cerebellar Neoplasms